Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year

Reuters
09/16
<a href="https://laohu8.com/S/CSBR">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year

Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10